|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EPHA6 |
Gene summary for EPHA6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EPHA6 | Gene ID | 285220 |
| Gene name | EPH receptor A6 | |
| Gene Alias | EHK-2 | |
| Cytomap | 3q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A0B4J1T8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 285220 | EPHA6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.92e-13 | 2.90e-01 | 0.0155 |
| 285220 | EPHA6 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.19e-20 | 5.56e-01 | -0.1808 |
| 285220 | EPHA6 | HTA11_2951_2000001011 | Human | Colorectum | AD | 5.78e-07 | 5.37e-01 | 0.0216 |
| 285220 | EPHA6 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.54e-29 | 8.21e-01 | -0.0811 |
| 285220 | EPHA6 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.06e-19 | 6.48e-01 | -0.1088 |
| 285220 | EPHA6 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.47e-26 | 5.04e-01 | -0.1954 |
| 285220 | EPHA6 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.02e-04 | 4.13e-01 | -0.2602 |
| 285220 | EPHA6 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.02e-09 | 4.82e-01 | -0.2196 |
| 285220 | EPHA6 | HTA11_3361_2000001011 | Human | Colorectum | AD | 9.33e-17 | 4.86e-01 | -0.1207 |
| 285220 | EPHA6 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.84e-09 | 4.28e-01 | -0.1526 |
| 285220 | EPHA6 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.81e-16 | 3.96e-01 | -0.1464 |
| 285220 | EPHA6 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.01e-06 | 2.45e-01 | -0.1001 |
| 285220 | EPHA6 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.05e-14 | 3.57e-01 | -0.059 |
| 285220 | EPHA6 | HTA11_2992_2000001011 | Human | Colorectum | SER | 6.85e-08 | 4.18e-01 | -0.1706 |
| 285220 | EPHA6 | HTA11_546_2000001011 | Human | Colorectum | AD | 3.18e-04 | 2.50e-01 | -0.0842 |
| 285220 | EPHA6 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.16e-02 | 3.47e-01 | 0.0451 |
| 285220 | EPHA6 | HTA11_10623_2000001011 | Human | Colorectum | AD | 7.94e-17 | 6.53e-01 | -0.0177 |
| 285220 | EPHA6 | HTA11_6801_2000001011 | Human | Colorectum | SER | 4.97e-04 | 3.04e-01 | 0.0171 |
| 285220 | EPHA6 | HTA11_6818_2000001011 | Human | Colorectum | AD | 5.79e-30 | 1.55e+00 | 0.0112 |
| 285220 | EPHA6 | HTA11_7469_2000001011 | Human | Colorectum | AD | 1.05e-02 | 3.49e-01 | -0.0124 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
| GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
| GO:0033674 | Colorectum | AD | positive regulation of kinase activity | 131/3918 | 467/18723 | 1.28e-04 | 1.85e-03 | 131 |
| GO:0007411 | Colorectum | AD | axon guidance | 64/3918 | 227/18723 | 5.41e-03 | 3.55e-02 | 64 |
| GO:0097485 | Colorectum | AD | neuron projection guidance | 64/3918 | 228/18723 | 6.02e-03 | 3.78e-02 | 64 |
| GO:00336741 | Colorectum | SER | positive regulation of kinase activity | 95/2897 | 467/18723 | 2.62e-03 | 2.41e-02 | 95 |
| GO:00074111 | Colorectum | SER | axon guidance | 51/2897 | 227/18723 | 3.29e-03 | 2.82e-02 | 51 |
| GO:00974851 | Colorectum | SER | neuron projection guidance | 51/2897 | 228/18723 | 3.61e-03 | 3.03e-02 | 51 |
| GO:00615641 | Colorectum | SER | axon development | 94/2897 | 467/18723 | 3.78e-03 | 3.13e-02 | 94 |
| GO:00074091 | Colorectum | SER | axonogenesis | 84/2897 | 418/18723 | 6.20e-03 | 4.49e-02 | 84 |
| GO:00336742 | Colorectum | MSS | positive regulation of kinase activity | 122/3467 | 467/18723 | 2.50e-05 | 5.21e-04 | 122 |
| GO:00074092 | Colorectum | MSS | axonogenesis | 105/3467 | 418/18723 | 4.32e-04 | 5.23e-03 | 105 |
| GO:00615642 | Colorectum | MSS | axon development | 115/3467 | 467/18723 | 5.33e-04 | 6.00e-03 | 115 |
| GO:0048013 | Colorectum | MSS | ephrin receptor signaling pathway | 17/3467 | 51/18723 | 8.28e-03 | 4.99e-02 | 17 |
| GO:00336743 | Colorectum | MSI-H | positive regulation of kinase activity | 53/1319 | 467/18723 | 3.99e-04 | 8.98e-03 | 53 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
| hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
| hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
| hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EPHA6 | SNV | Missense_Mutation | c.1720N>C | p.Tyr574His | p.Y574H | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD | ||
| EPHA6 | SNV | Missense_Mutation | rs748675557 | c.727N>A | p.Asp243Asn | p.D243N | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR | |
| EPHA6 | SNV | Missense_Mutation | novel | c.1246N>A | p.Asp416Asn | p.D416N | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| EPHA6 | SNV | Missense_Mutation | novel | c.1835N>T | p.Arg612Ile | p.R612I | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EPHA6 | SNV | Missense_Mutation | novel | c.2171N>T | p.Arg724Ile | p.R724I | protein_coding | tolerated(0.38) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EPHA6 | SNV | Missense_Mutation | rs780254423 | c.979N>T | p.Arg327Trp | p.R327W | protein_coding | deleterious(0) | probably_damaging(0.924) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| EPHA6 | SNV | Missense_Mutation | c.1823N>C | p.His608Pro | p.H608P | protein_coding | deleterious(0.01) | possibly_damaging(0.69) | TCGA-GI-A2C8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Adriamycin | SD | ||
| EPHA6 | deletion | Frame_Shift_Del | rs765418329 | c.2494delN | p.Arg834GlyfsTer8 | p.R834Gfs*8 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| EPHA6 | deletion | Frame_Shift_Del | novel | c.856delN | p.Ala287ArgfsTer45 | p.A287Rfs*45 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| EPHA6 | SNV | Missense_Mutation | c.520G>A | p.Glu174Lys | p.E174K | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 285220 | EPHA6 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
| 285220 | EPHA6 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE | inhibitor | CHEMBL24828 | VANDETANIB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |